Monogram Technologies Inc. (NASDAQ: MGRM) related to its sale to Zimmer Biomet Holdings, Inc. Under the terms of the proposed transaction, Monogram shareholders would receive an upfront payment of $4.04 per share in cash, and one non-tradeable contingent value right collectively worth up to $12.37 per share in cash payable (i) $1.04 upon completion of a proof-of-concept demonstration of Monogram’s robotic system for unicompartmental (partial) knee arthroplasty made available to Zimmer’s designated executives on or before the later January 31, 2026 or 30 days following the Closing; (ii) $1.08 upon the grant of 510(k) clearance by the FDA for Monogram’s fully autonomous robotic system for use with Zimmer implants, as evidenced by formal clearance indicating substantial equivalence to a predicate device, on or before December 31, 2027; (iii) $3.41 when the company achieves gross revenue of at least $156 million between January 1, 2028 and December 31, 2028; (iv) $3.41 when the company achieves gross revenue of at least $381 million between January 1, 2029 and December 31, 2028; and (v) $3.43 when the company achieves gross revenue of at least $609 million between January 1, 2030 and December 31, 2030.